Bcl-2 was the ®rst identi®ed genetic regulator of apoptosis in mammals (Tsujimoto et al., 1985; Vaux et al., 1988; Hockenberry et al., 1990) , and its expression is associated with prolonged cell survival through inhibition of a ®nal common pathway of cell death. In addition to inhibiting cell death, overexpression of bcl-2 protein can prevent or markedly reduce cell killing induced by multiple chemotherapeutic drugs as well as by gamma-irradiation, and can result in a poor response to therapy in some neoplastic disorders (Reed, 1994) . In human epithelial cancer, the extended cell lifespan conferred by bcl-2 upregulation may permit the accumulation of additional genetic alterations required for tumour development. Bcl-2 has been found to play a role in neoplastic progression in the large intestine (Hague et al., 1994) , though this role remains speculative. Most colorectal cancers develop from normal colonic epithelium through benign precursor lesions called adenomas. In normal large intestine, bcl-2 is expressed in the epithelial regenerative compartment in the base of crypts and is absent from the upper regions of the crypt and the luminal surface. In contrast, 80 ± 90% of adenomas show strong cytoplasmic staining throughout dysplastic crypts though the distribution of such strongly staining crypts is patchy (Hague et al., 1994; Kaklamanis et al., 1996) . Aberrant expression of bcl-2 is retained in a subset of carcinomas (50 ± 75% of cases) and the pattern of staining changes at the adenoma-carcinoma transition from ordered granular cytoplasmic staining similar to that found in normal colonic crypt stem cells to poorly organized diuse staining. Interestingly, Bronner et al. (1995) demonstrated increased expression in non-dysplastic epithelium immediately adjacent to the primary lesion in several cases (4/26 adenomas and 11/26 adenocarcinomas), but not in tissues adjacent to metastases or to the base of normal crypts. Hence, dysregulation of bcl-2 expression is an early event in the development of colorectal cancers.
The genetic mechanisms governing the dysregulation of bcl-2 expression in colorectal tumour development are yet to be explained, since no causative genetic alterations have yet been identi®ed in the bcl-2 gene itself in this setting (Pietenpol et al., 1994) . Studies by Young and Korsmeyer (1993) and Miyashita et al. (1994) have indicated the presence of a p53 negative regulatory element in the P2 promoter region of bcl-2. In addition, bcl-2 and p53 have been postulated to regulate a common pathway in colorectal carcinogenesis (Sinicrope et al., 1995) . Since p53 is commonly mutated in colorectal cancers, but rarely in those colorectal cancers showing microsatellite instability (MSI) (Cottu et al., 1996; Konishi et al., 1996; Simms et al., 1998) , it was of interest to determine how bcl-2 overexpression related to MSI. Therefore, the primary aim of this study was to examine the relationship of bcl-2 protein expression to clinicopathological and molecular variables including evidence of p53 mutation and the presence of MSI.
Studies in haemopoietic cells suggest that upregulation of c-myb may be responsible for increased expression of bcl-2 because DNA footprinting assays showed protection of the P2 promoter in bcl-2 by cmyb (Frampton et al., 1996; Taylor et al., 1996; Salomoni et al., 1997) . Moreover, altered expression of c-myb in colorectal cancer cell lines may be associated with deletions within microsatellite DNA in transcriptional attenuator regions located in intron 1 of c-myb (Thompson et al., 1997) . Hence, a further aim of the study was to analyse deletions in mononucleotide regions in intron 1 of c-myb for association with bcl-2 protein expression.
The study was performed on a selected series of 71 colorectal carcinomas derived from a cohort previously characterized for clinicopathological and molecular features including microsatellite instability . Of these, 17 were MSI-high tumours (with band shifts in at least three of six markers), 16 were MSI-low tumours (with band shifts at one or two microsatellite markers), and 38 tumours were MSI-null. Methods are described in detail in ®gure legends.
Clinicopathological data from the selected series of 71 colorectal cancers is shown in Table 1 . Positive tumour cells for both bcl-2 and p53 antibodies were quanti®ed by two independent pathologists, expressed as a percentage of the total number of tumour cells, and assigned to one of the ®ve categories: 0, 45%; 1, 6 ± 25%; 2, 26 ± 50%; 3, 51 ± 75%; and 4, 576%. To de®ne negative tumours, the cut-o of 45% positive cells was used. Expression of bcl-2 protein was found in 53/71 Figure 1 Protein expression of bcl-2. Slides for immunostaining were cut from routinely processed paran-embedded blocks obtained from the Department of Pathology, Royal Brisbane Hospital. Bcl-2 and p53 protein expression was determined by immunohistochemical staining performed on 5-mm deparanized sections, mounted on charge coated glass slides, using an avidinbiotinylated streptavidin complex with diaminobenzidine tetrahydrochloride as the chromogen. The bcl-2 antibody used was the monoclonal mouse anti-human antibody Clone 124 (Dako) at a 1 : 40 titer with overnight incubation with the section at 48C. A section of human tonsil was included with each series as an external positive control. In sections of colorectal cancer that were otherwise negative for bcl-2 staining, positive staining of basal crypt cells in adjacent normal mucosa, in ganglion cells, and in lymphocytes was used as an internal control. Omission of the primary antibody served as a negative control. (Top) Bcl-2 staining of the basal crypts in normal colonic mucosa; (middle) poorly dierentiated colon cancer showing no expression of bcl-2 protein (score 0); (bottom) well dierentiated colorectal cancer strongly positive for bcl-2(score 3). All pictures620 magni®cation (Figure 2 ). Positive staining for bcl-2 was observed in 33/38 MSI-null cancers (87%), 10/16 MSI-low cancers (63%) and 10/17 MSI-high cancers (59%). MSI was observed in both polyT repeats of cmyb only in the 17 MSI-high cancers, and this occurred regardless of the level of bcl-2 protein expression (Figure 3 ). Patients whose tumours stained positively for bcl-2 showed improved survival (P=0.012, Gehan Wilcoxon test) (Figure 4) , though no signi®cant correlation with survival was seen with the extent of staining. A weak association was seen between tumour dierentiation and bcl-2 protein expression but this did not attain statistical signi®cance (P=0.056). No signi®cant relationships were found between bcl-2 expression and age, sex, site, type and clinicopathological stage. Allelic loss of p53 was observed in 28/60 informative tumours (47%), but in none of ten informative tumours from the MSI-high group. Detectable expression of p53 protein nearly always re¯ects its mutation and consequent increase in stability (Kastan et al., 1991; Kuerbitz et al., 1992) . Expression of p53 protein was detected in 61 of 69 tumours tested (88%). The MSIhigh group displayed low expression (45% positive cells) with an average score of 0.79, the MSI-low group had an average expression score of 2.34 (25 ± 75% positive cells), and the MSI-null group had an average p53 expression of 2.33 (25 ± 75% positive cells). When the average score for the MSI-high group was compared with the combined scores of the MSI-low and MSI-null groups, a signi®cant dierence was found (P50.001, Student's t-test). Importantly, there was no relationship demonstrated between evidence of p53 mutation (p53 allelic loss or p53 immunostaining) and expression of bcl-2 (P40.05). Figure 5 shows examples of p53 mutation analysis.
The neoplastic transformation of colorectal epithelium has been reported to be associated with increasing inhibition of apoptosis (Bedi et al., 1995) . Bcl-2, which inhibits apoptosis, has been postulated to play a role in the early establishment of colorectal tumours (Hague et al., 1994) . A subset of colorectal carcinomas develops via an alternative pathway involving defects in the mismatch repair system. In such cancers, mutations in p53, which is a negative regulator of bcl-2, are rare (Cottu et al., 1996; Konishi et al., 1996; Simms et al., 1998) . In this study we have shown a reciprocal association exists between the expression of bcl-2 and MSI. However, when evidence of p53 mutation was directly tested for association with bcl-2, no signi®cant relationships were found. Since colorectal cancers tested in this study expressed bcl-2 in the absence of any evidence of p53 mutation, it is likely that alternative mechanisms may be acting to regulate the expression of bcl-2. Bcl-2 was expressed signi®cantly less often in both the MSI-high and the MSI-low groups. MSI-high colorectal cancers do not show evidence of p53 mutations whilst MSI-low colorectal cancers show evidence of high levels p53 mutations . This represents further evidence that expression of bcl-2, in colorectal cancers at least, is independent of p53 mutation, since there are signi®cant dierences between these two groups with respect to the level of p53 mutations. Further, Sinicrope et al. (1995) and Watson et al. (1996) both report a lack of direct association between bcl-2 and p53 expression in colorectal tumorigenesis. Microsatellite instability is the hallmark of mismatch repair de®ciency in cancers and mostly occurs in anonymous sequences of repetitive DNA. Should this occur in coding or regulatory sequences, genes may be inactivated. Microsatellite instability was detected in both polythymidine tracts of a regulatory region of cmyb in all MSI-high cancers in this study, but no instability in c-myb was seen in any MSI-low or MSInull cancers. The c-myb instability present in MSI-high cancers had no apparent in¯uence on the level of expression of bcl-2 protein. Of interest however, the second polythymidine tract in c-myb (T22) was rarely polymorphic and fully speci®c in detecting the MSIhigh cancers in this study and thus was established to be a useful marker for screening the MSI status of colorectal cancers.
A signi®cant survival advantage was shown to be associated with bcl-2 protein expression in this study. Bcl-2 expression as an independent prognostic marker for patients with colorectal cancer has been reported previously (Ofner et al., 1995) . Association of bcl-2 with a favourable clinical outcome has also been reported in ovarian cancer (Henriksen et al., 1995) . Given the described role of bcl-2 as an inhibitor of apoptosis, these results are somewhat paradoxical. In the colon, improved survival may be explained because bcl-2 is highly expressed in adenomas and less so in carcinomas (Hague et al., 1994) . Hence those cancers which retain their expression of bcl-2 protein are likely to be less aggressive and more adenoma-like. In addition, in our tumours, there was a weak association between bcl-2 expression and a moderate to high dierentiation level, which also suggests a less aggressive phenotype. This feature suggests that bcl-2 expression in colorectal tumours is not merely a re¯ection of dierentiation level, as the undierentiated normal stem cell in colonic crypts highly expresses this protein, whereas in the cancer, it is the well dierentiated cells which have the highest expression.
Several other reports provide supporting evidence for the association of bcl-2 protein expression with a b Figure 5 Evidence of p53 mutation. DNA was extracted from each tumour and a constitutional control (either normal colon or lymphocytes) by a modi®ed salt precipitation technique (Miller et al., 1988) . Evidence of p53 mutation was sought using loss of heterozygosity analysis and immunohistochemistry. All tumours were assessed for allelic loss on chromosome 17p by an intronic CA repeat within the p53 gene (Jones and Nakamura, 1992) . Ampli®ed products incorporating [a-33 P]dATP from the p53-CA microsatellite were separated on 5% denaturing polyacrylamide gels run at 65 W for 1.5 ± 2 h, dried, and then exposed to X-ray ®lm for 1 ± 3 days. Those tumours which exhibited microsatellite instability with this marker, making assessment of allelic loss impossible, were further analysed for loss with a PCR-RFLP from exon 4 of the p53 gene (Olschwang et al., 1991; Meltzer et al., 1991) . Ampli®ed products for PCR-RFLP analysis were digested with BstUI for 3 h at 608C then separated on 12% nondenaturing polyacrylamide gels and stained with ethidium bromide. Allelic loss was scored visually and conservatively in all heterozygotes by two independent observers. p53 protein was detected using the monoclonal mouse anti-human Clone DO7 antibody (Dako). (a) L-R: tumours tested with the p53-CA microsatellite; MSI in ®rst normal-tumour pair, and allelic loss in the second; a tumour tested with PCR-RFLP analysis showing allelic loss of p53 (horizontal arrow indicates MSI; vertical arrows indicate LOH). (b) positive staining for p53 protein in a colorectal cancer decreased aggression. Pietenpol et al. (1994) demonstrated that overexpression of bcl-2 protein can actually inhibit the growth of some colorectal cancer cell lines. Though the levels of bcl-2 were similar in the cell lines tested, profound suppression occurred in two of three colorectal cell lines. It is therefore likely, that the eect of bcl-2 expression depends upon its cellular context. In a function separate from its cell survival role, bcl-2 has been reported to enhance withdrawal from the cell cycle, which also may in¯uence the aggressiveness of a cancer (Vairo et al., 1996) . This data was also indicative of an eect of cellular context. Mismatch repair de®cient colorectal cancers are reported to be associated with better patient survival (Thibodeau et al., 1993; Lukish et al., 1998) , and such cancers are more likely to be poorly dierentiated conferring a worse prognosis (Bjerkeset et al., 1987; Sun et al., 1996) . Conversely, we have shown bcl-2 expression gives a better patient prognosis but expression of this protein is low in mismatch repair de®cient cancers. Thus, certain paradoxical situations have been shown to exist involving survival-related variables in mismatch repair de®cient cancers and it is likely that such variables act independently of each other on patient survival.
